NCT06916130View on ClinicalTrials.gov

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
DRUG

AD-120A

Administered before the breakfast during 7 days, Oral, Tablet

DRUG

AD-120

Administered before the breakfast during 7 days, Oral, Tablet

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY